BARBARA JANE O'BRIEN to Treatment Outcome
This is a "connection" page, showing publications BARBARA JANE O'BRIEN has written about Treatment Outcome.
Connection Strength
0.061
-
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1637-1644.
Score: 0.014
-
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
Score: 0.012
-
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. Neuro Oncol. 2022 10 03; 24(10):1726-1735.
Score: 0.012
-
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
Score: 0.009
-
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494.
Score: 0.008
-
Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol. 2015 Sep; 124(3):501-6.
Score: 0.007